ArticleCureus2025
Characterization of Patients With Obstructive Sleep Apnea Syndrome Undergoing Drug-Induced Sleep Endoscopy: A Retrospective Study of Nine Years (2014-2022).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionObstructive sleep apnea syndrome (OSAS) is the most prevalent sleep-related breathing disorder associated with an increased risk of cardiovascular and cerebrovascular complications. Identifying the anatomical sites of airway obstruction is crucial for optimizing treatment, particularly in patients requiring surgical intervention. In recent years, drug-induced sleep endoscopy (DISE) has emerged as a valuable diagnostic tool for evaluating upper airway obstruction in OSAS patients.
objectivesTo characterize the OSAS population undergoing DISE and correlate endoscopic findings with patient characteristics and obstruction sites. MATERIALS AND
methodsA retrospective study was conducted by reviewing medical records of patients who underwent DISE between 2014 and 2022 at Hospital da Senhora da Oliveira, Guimarães. The analyzed variables included age, gender, body mass index (BMI), apnea-hypopnea index (AHI), and the level and pattern of obstruction based on the velum, oropharynx, tongue, and epiglottis (VOTE) classification. Statistical analysis was performed using IBM SPSS Statistics v27.0 (IBM Corp., Armonk, USA).
resultsA total of 71 patients underwent DISE, with ages ranging from 25 to 68 years. The majority were male (84%, n=60). Regarding BMI distribution, 18.3% (n=13) of patients were classified as obese, 67.6% (n=48) as overweight, and 14.1% (n=10) had a normal weight. Most patients had moderate OSAS (56.3%, n=40), followed by severe (26.8%, n=19) and mild OSAS (16.9%, n=12). A significant positive correlation was observed between AHI and BMI (p=0.028). Multilevel obstruction was identified in 75% of patients, with the most common collapse site being the soft palate, followed by the oropharynx, base of the tongue, and epiglottis. No statistically significant differences were found in the obstruction site, pattern, or severity based on AHI or BMI. However, at the palatal level, a positive trend was observed between AHI and obstruction severity (r=0.153; p>0.05).
conclusionsDISE is a safe and reliable diagnostic modality for identifying upper airway collapse sites, revealing anatomical alterations that may not be apparent during standard physical examination. This technique plays a crucial role in evaluating patients considered for surgical intervention or those who have not responded to first-line therapies. DISE enables a personalized approach to OSAS management by tailoring treatment strategies to individual patient anatomy and obstruction patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.